CHEN Wei-Qi, MA Lin, JING Jing, WANG Yi-Long, WANG Yong-Jun. The Individualized Therapy for High Risk Non-Disabling Ischemic Cerebrovascular Events[J]. Chinese Journal of Stroke, 2018, 13(05): 489-493.
[1] GONG X,ZOU X,LIU L,et al. Prognostic valueof inflammatory mediators in 1-year outcome ofacute ischemic stroke with middle cerebral arterystenosis[J/OL]. Mediators Inflamm,2013,2013:850714. https://doi.org/10.1155/2013/850714.[2] LI J,WANG Y,LIN J,et al. Soluble CD40L is auseful marker to predict future strokes in patientswith minor stroke and transient ischemic attack[J].Stroke,2015,46(7):1990-1992.[3] LIN J,ZHENG H,CUCCHIARA B L,et al.Association of Lp-PLA2-A and early recurrenceof vascular events after TIA and minor stroke[J].Neurology,2015,85(18):1585-1591.[4] MULLEN M T,MESSE S R,KASNER S E,et al.Anti-Phosphatidylserine-Prothrombin Antibodiesare Associated with Outcome in a TIA Cohort[J/OL].Front Neurol,2012,3:137. https://doi.org/10.3389/fneur.2012.00137.[5] GREISENEGGER S,SEGAL H C,BURGESS AI,et al. Biomarkers and mortality after transientischemic attack and minor ischemic stroke:Population-based study[J]. Stroke,2015,46(3):659-666.[6] LI J,WANG Y,WANG D,et al. Glycated albuminpredicts the effect of dual and single antiplatelettherapy on recurrent stroke[J]. Neurology,2015,84(13):1330-1336.[7] LIU L,WONG K S,LENG X,et al. Dualantiplatelet therapy in stroke and ICAS:Subgroupanalysis of CHANCE[J]. Neurology,2015,85(13):1154-1162.[8] JOHNSTON S C,AMARENCO P,ALBERS GW,et al. Ticagrelor versus aspirin in acute stroke ortransient ischemic attack[J]. N Engl J Med,2016,375(14):1395.[9] WANG Y,ZHAO X,LIN J,et al. AssociationBetween CYP2C19 Loss-of-Function Allele Statusand Efficacy of Clopidogrel for Risk ReductionAmong Patients With Minor Stroke or TransientIschemic Attack[J]. JAMA,2016,316(1):70-78.[10] WALLENTIN L,BECKER R C,BUDAJ A,et al.Ticagrelor versus clopidogrel in patients with acutecoronary syndromes[J]. N Engl J Med,2009,361(11):1045-1057.[11] WANG Y,LIN Y,MENG X,et al. Effect ofticagrelor with clopidogrel on high on-treatmentplatelet reactivity in acute stroke or transientischemic attack(PRINCE)trial:Rationale anddesign[J]. Int J Stroke,2017,12(3):321-325.[12] WIVIOTT S D,ANTMAN E M,WINTERS K J,et al. Randomized comparison of prasugrel(CS-747,LY640315),a novel thienopyridine P2Y12antagonist,with clopidogrel in percutaneouscoronary intervention:results of the Joint Utilizationof Medications to Block Platelets Optimally(JUMBO)-TIMI 26 trial[J]. Circulation,2005,111(25):3366-3373.[13] EZEKOWITZ M D,REILLY P A,NEHMIZ G,etal. Dabigatran with or without concomitant aspirincompared with warfarin alone in patients with nonvalvular atrial fibrillation(PETRO Study)[J].Am J Cardiol,2007,100(9):1419-1426.[14] CONNOLLY S J,EZEKOWITZ M D,YUSUF S,etal. Dabigatran versus warfarin in patients with atrialfibrillation[J]. N Engl J Med,2009,361(12):1139-1151.[15] PATEL M R,MAHAFFEY K W,GARG J,et al.Rivaroxaban versus warfarin in nonvalvular atrialfibrillation[J]. N Engl J Med,2011,365(10):883-891.